Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 9/20 | 0.82 |
| ▸ | MRGPRX1 | Q96LB2 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL872386 | 0.92 | TLR4 (0.79) | TLR4LMNAALDH1A1KDM4EMAPT | |
| SCHEMBL871916 | 0.92 | TLR4 (0.82) | TLR4MRGPRX1ALDH1A1MEN1KMT2A | |
| Resatorvid SCHEMBL29607069 | 0.90 | TLR4 (1.00) | TLR4MRGPRX1HRH1LMNAKMT2A | |
| Resatorvid SCHEMBL30113148 | 0.90 | TLR4 (1.00) | TLR4MRGPRX1HRH1LMNAKMT2A | |
| Resatorvid SCHEMBL871572 | 0.90 | TLR4 (1.00) | TLR4MRGPRX1HRH1LMNAKMT2A | |
| Resatorvid SCHEMBL1821271 | 0.90 | TLR4 (1.00) | TLR4MRGPRX1HRH1LMNAKMT2A | |
| Resatorvid SCHEMBL872197 | 0.90 | TLR4 (1.00) | TLR4MRGPRX1HRH1LMNAKMT2A | |
| SCHEMBL871621 | 0.89 | TLR4 (0.78) | TLR4LMNAALDH1A1KDM4E | |
| SCHEMBL871496 | 0.88 | TLR4 (0.82) | TLR4MRGPRX1HRH1LMNAMAPT | |
| SCHEMBL872915 | 0.88 | TLR4 (0.75) | TLR4MRGPRX1LMNAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110184034-A1 | Severe sepsis preventive therapeutic agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-28 | — | — | US | claimed |
| US-7960416-B2 | Oil-in-water emulsion of a 1-carboxylate-6-arylsulfamoyl cyclohexene and synthetic and naturally occurring phospholipids; nitric oxide or cytokine prodution inhibitors; cardiovascular disorders, autoimmune dieseases, septic shock; improved stability during autoclave sterilization | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | claimed |
| EP-2255785-A2 | Stable emulsion composition | Takeda Pharmaceutical Company Limited (JP) | 2010-12-01 | — | — | EP | claimed |
| US-20100016381-A1 | STABLE EMULSION COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | claimed |
| EP-1875926-A1 | STABLE EMULSION COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2008-01-09 | — | — | EP | claimed |
| EP-1254659-B1 | STABLE EMULSION COMPOSITIONS | TAKEDA PHARMACEUTICAL (JP) | 2006-11-15 | — | — | EP | claimed |
| US-20050272701-A1 | Pharmaceutical composition | ASAKAWA NAOKI | 2005-12-08 | — | — | US | claimed |
| US-6951885-B2 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-04 | — | — | US | claimed |
| EP-1524263-A1 | prodrugs containing cycloalkene derivatives | Takeda Pharmaceutical Company Limited (JP) | 2005-04-20 | — | — | EP | claimed |
| EP-1063228-B1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND USE | TAKEDA PHARMACEUTICAL (JP) | 2005-01-19 | — | — | EP | claimed |
| US-20040253276-A1 | Stable emulsion composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-16 | — | — | US | claimed |
| EP-1420783-A1 | STABLE EMULSION COMPOSITION | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | claimed |
| US-20030216475-A1 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-11-20 | — | — | US | claimed |
| US-20030212114-A1 | Stable emulsion compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-11-13 | — | — | US | claimed |
| EP-1310248-A1 | PHARMACEUTICAL COMPOSITION | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | claimed |
| WO-2003013513-A1 | STABLE EMULSION COMPOSITION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-20 | — | — | WO | claimed |
| US-6495604-B1 | SUCH AS D-ETHYL-6-(N-(2,4-DIFLUOROPHENYL)SULFAMOYL)-1-CYCLOHEXENE-1-CARBOXYLATE FOR INHIBITING NITRIC OXIDE AND/OR CYTOKINE PRODUCTION; FOR PREVENTING OR TREATING CARDIAC DISEASE, AUTOIMMUNE DISEASE OR SEPTIC SHOCK | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-17 | — | — | US | claimed |
| EP-1254659-A1 | STABLE EMULSION COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | claimed |
| EP-1063228-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2000-12-27 | — | — | EP | claimed |
| US-20160166526-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20150203464-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20150051256-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
| US-8901171-B2 | Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20130345304-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-26 | — | — | US | disclosed |
| US-20130046000-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-02-21 | — | — | US | disclosed |
| EP-2528598-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI - CANCER AGENT | Takeda Pharmaceutical Company Limited (JP) | 2012-12-05 | — | — | EP | disclosed |
| US-20120077856-A1 | PHARMACEUTICAL PRODUCT | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-03-29 | — | — | US | disclosed |
| EP-2366389-A1 | Severe sepsis preventive therapeutic agent | Takeda Pharmaceutical Company Limited (JP) | 2011-09-21 | — | — | EP | disclosed |
| WO-2011093512-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI - CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-04 | — | — | WO | disclosed |
| US-20110184034-A1 | Severe sepsis preventive therapeutic agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-28 | — | — | US | disclosed |
| US-7960416-B2 | Oil-in-water emulsion of a 1-carboxylate-6-arylsulfamoyl cyclohexene and synthetic and naturally occurring phospholipids; nitric oxide or cytokine prodution inhibitors; cardiovascular disorders, autoimmune dieseases, septic shock; improved stability during autoclave sterilization | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| EP-2260869-A2 | Pharmaceutical product | Takeda Pharmaceutical Company Limited (JP) | 2010-12-15 | — | — | EP | disclosed |
| EP-2255785-A2 | Stable emulsion composition | Takeda Pharmaceutical Company Limited (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20100016381-A1 | STABLE EMULSION COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20090105314-A1 | Pharmaceutical Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-04-23 | — | — | US | disclosed |
| US-20090062355-A1 | Pharmaceutical Product | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-03-05 | — | — | US | disclosed |
| EP-2018855-A1 | PHARMACEUTICAL AGENT | Takeda Pharmaceutical Company Limited (JP) | 2009-01-28 | — | — | EP | disclosed |
| EP-2018872-A1 | PHARMACEUTICAL PRODUCT | Takeda Pharmaceutical Company Limited (JP) | 2009-01-28 | — | — | EP | disclosed |
| EP-1875926-A1 | STABLE EMULSION COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2008-01-09 | — | — | EP | disclosed |
| US-7247653-B2 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-24 | — | — | US | disclosed |
| EP-1254659-B1 | STABLE EMULSION COMPOSITIONS | TAKEDA PHARMACEUTICAL (JP) | 2006-11-15 | — | — | EP | disclosed |
| US-7105572-B2 | Stable emulsion compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-09-12 | — | — | US | disclosed |
| US-20060058288-A1 | Severe sepsis preventive therapeutic agent | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2006-03-16 | — | — | US | disclosed |
| US-20050272701-A1 | Pharmaceutical composition | ASAKAWA NAOKI | 2005-12-08 | — | — | US | disclosed |
| US-6951885-B2 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-04 | — | — | US | disclosed |
| EP-1524263-A1 | prodrugs containing cycloalkene derivatives | Takeda Pharmaceutical Company Limited (JP) | 2005-04-20 | — | — | EP | disclosed |
| EP-1063228-B1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND USE | TAKEDA PHARMACEUTICAL (JP) | 2005-01-19 | — | — | EP | disclosed |
| EP-1495756-A1 | SEVERE SEPSIS PREVENTIVE THERAPEUTIC AGENT | Takeda Chemical Industries, Ltd. (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-20040253276-A1 | Stable emulsion composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1420783-A1 | STABLE EMULSION COMPOSITION | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-20040063685-A1 | Cycloalkene antisepsis drug with antibacterial, antifungal, nonsteroidal antiinflammatory, steroid and/or anticoagulant agents | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20030216475-A1 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-11-20 | — | — | US | disclosed |
| US-20030212114-A1 | Stable emulsion compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1348443-A1 | COMBINATION DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-01 | — | — | EP | disclosed |
| EP-1310248-A1 | PHARMACEUTICAL COMPOSITION | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| WO-2003013513-A1 | STABLE EMULSION COMPOSITION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-20 | — | — | WO | disclosed |
| US-6495604-B1 | SUCH AS D-ETHYL-6-(N-(2,4-DIFLUOROPHENYL)SULFAMOYL)-1-CYCLOHEXENE-1-CARBOXYLATE FOR INHIBITING NITRIC OXIDE AND/OR CYTOKINE PRODUCTION; FOR PREVENTING OR TREATING CARDIAC DISEASE, AUTOIMMUNE DISEASE OR SEPTIC SHOCK | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| EP-1254659-A1 | STABLE EMULSION COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
| EP-1063228-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2000-12-27 | — | — | EP | disclosed |
| EP-1063228-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2000-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345304-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | TLR4 2222/4885MRGPRX1 1567/4885HRH1 3638/4885 |
| US-20040063685-A1 | Cycloalkene antisepsis drug with antibacterial, antifungal, nonsteroidal antiinflammatory, steroid and/or anticoagulant agents | ELANE, MMP8, SERPINC1 | TLR4 567/4885MRGPRX1 747/4885HRH1 562/4885 |
| US-20030212114-A1 | Stable emulsion compositions | AHR, NR1H2, NR1H3 | TLR4 2050/4885MRGPRX1 651/4885HRH1 39/4885 |
| US-20090105314-A1 | Pharmaceutical Agent | TLR1, TLR6, TPMT | TLR4 8/4885MRGPRX1 467/4885HRH1 2465/4885 |
| US-20050272701-A1 | Pharmaceutical composition | CEL, HSD17B7, ABCG2 | TLR4 2497/4885MRGPRX1 2159/4885HRH1 2160/4885 |
| US-20090062355-A1 | Pharmaceutical Product | ATF1, ATF4, TLR8 | TLR4 13/4885MRGPRX1 275/4885HRH1 1809/4885 |
| US-20060058288-A1 | Severe sepsis preventive therapeutic agent | TLR1, TLR5, TLR4 | TLR4 3/4885MRGPRX1 183/4885HRH1 1205/4885 |
| US-20150203464-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | TLR4 2222/4885MRGPRX1 1567/4885HRH1 3638/4885 |
| US-20130046000-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | TLR4 2222/4885MRGPRX1 1567/4885HRH1 3638/4885 |
| US-20110184034-A1 | Severe sepsis preventive therapeutic agent | TLR1, TLR5, TLR4 | TLR4 3/4885MRGPRX1 179/4885HRH1 1118/4885 |
| US-20160166526-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | TLR4 2222/4885MRGPRX1 1567/4885HRH1 3638/4885 |
| US-20040253276-A1 | Stable emulsion composition | PHOSPHO1, SGMS1, SGMS2 | TLR4 3985/4885MRGPRX1 2890/4885HRH1 3335/4885 |
| US-20030216475-A1 | Pharmaceutical composition | ARRB1, ADRA1B, ADRB1 | TLR4 2126/4885MRGPRX1 1041/4885HRH1 44/4885 |
| US-20120077856-A1 | PHARMACEUTICAL PRODUCT | ATF1, ATF4, TLR8 | TLR4 13/4885MRGPRX1 275/4885HRH1 1809/4885 |
| US-20150051256-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | TLR4 2222/4885MRGPRX1 1567/4885HRH1 3638/4885 |
| US-20100016381-A1 | STABLE EMULSION COMPOSITION | LIPA, PHOSPHO1, CEL | TLR4 3789/4885MRGPRX1 1867/4885HRH1 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.